Prasugrel Inappropriate Use in Patients Post-percutaneous coronary intervention (PCI). A Single Center Study

Prasugrel Inappropriate Use in Patients Post-percutaneous coronary intervention (PCI). A Single Center Study

Prasugrel is a thienopyridine that was approved by the US Food and Drug Administration (FDA) in combination with aspirin for the reduction of thrombotic events as well as stent thrombosis in patients with ACS who undergo PCI. This retrospective study aims to assess the frequency of inappropriate use...

Full description

Bibliographic Details
Main Authors: Ahmed Amro, Kanaan Mansoor, Mohammad Amro, Amal Sobeih, Obadah Aqtash, Hisham Hirzallah, Alaa Gabi, Madhulika Urella, Waseem Ahmed, Sandra Shenouda, Rameez Sayyed
Format: Article
Language:English
Published: Marshall University 2019-07-01
Series:Marshall Journal of Medicine
Subjects:
Prasugrel
inappropriate use
Coronary intervention
DAPT
Online Access:https://mds.marshall.edu/cgi/viewcontent.cgi?article=1220&context=mjm

Internet

https://mds.marshall.edu/cgi/viewcontent.cgi?article=1220&context=mjm

Similar Items